Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice

Publisher： Karger

E-ISSN： 1421-9913|76|1-2|40-47

ISSN： 0014-3022

Source： European Neurology, Vol.76, Iss.1-2, 2016-07, pp. : 40-47

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and Glatiramer Acetate

By  

European Neurology, Vol. 65, Iss. 4, 2011-03 ,pp. : 231-232

Karger

Access to resources Recommend Favorite

Interferon-β1b in Multiple Sclerosis: Effect on Progression of Disability and Clinical Markers of Treatment Response

By  

European Neurology, Vol. 60, Iss. 6, 2008-09 ,pp. : 279-284

Karger

Access to resources Recommend Favorite

Apolipoprotein Alleles and the Response to Interferon-β-1b in Multiple Sclerosis

By  

European Neurology, Vol. 65, Iss. 3, 2011-02 ,pp. : 132-137

Karger

Access to resources Recommend Favorite

Patterns of Th1/Th2 Cytokines Predict Clinical Response in Multiple Sclerosis Patients Treated with Glatiramer Acetate

By  

European Neurology, Vol. 65, Iss. 3, 2011-03 ,pp. : 164-169

Karger

Access to resources Recommend Favorite

Anaphylactic Reaction after Injection of Glatiramer Acetate (Copaxone®) in Patients with Relapsing-Remitting Multiple Sclerosis

By  

European Neurology, Vol. 66, Iss. 6, 2011-11 ,pp. : 368-370

Karger

Access to resources Recommend Favorite